Abstract
Emerging data suggest that despite an increased number of peer-reviewed articles submitted to journals during the pandemic, women have published fewer papers than men thus far this year. In this study, we provide timely analysis to compare the gender distribution of clinical trial leadership in COVID-19 clinical trials. We demonstrate that less than one-third of COVID-19-related clinical trials are led by principal investigators who were predicted to be women, half the proportion observed in non-COVID-19 (breast cancer and T2DM) trials over the same period. These gender disparities during the pandemic may indicate not only a lack of women's leadership in international clinical trials and involvement in new projects but also may reveal imbalances in women's access to research activities and funding during health emergencies. The COVID-19 pandemic offers numerous opportunities for research and leadership that could equalize opportunity in a new field, but our results suggest the opposite. Our demonstration of gender differences in trial leadership and grant allocation argue for revised policies and strategies that encourage the participation of women in pandemic research. Not only can these women drive discovery and innovation, but they can act to address health disparities and provide role models for the next generation of women scientists.
Competing Interest Statement
Competing interests declared in the manuscript
Funding Statement
No funding received
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Not applicable
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The repository of the datasets used to collect and analyse the data available at https://osf.io/k2r57/.
